Flexxon Biosciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.40 Cr
- Revenue Growth 44.81%
- Profit Growth 25.15%
- Ebitda 207.57%
- Net Worth 18.79%
- Total Assets 18.05%
About Flexxon Biosciences
Flexxon Biosciences Private Limited (FBPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 November 2017 (Seven years and three months 2 days old ). Its registered office is in Meerut, Uttar Pradesh, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.40 Cr.
Pravesh, Sanjay Rajput, Subhash Tomar, and One other member serve as directors at the Company.
Company Details
-
Location
Meerut, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2017PTC098579
-
Company No.
098579
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Nov 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Flexxon Biosciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pravesh
|
Director | 14-Nov-2017 | Current |
|
Sanjay Rajput
|
Director | 14-Nov-2017 | Current |
|
Subhash Tomar
|
Director | 14-Nov-2017 | Current |
|
Sanjeev Malik
|
Director | 14-Nov-2017 | Current |
Financial Performance of Flexxon Biosciences.
Flexxon Biosciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 44.81% increase. The company also saw a substantial improvement in profitability, with a 25.15% increase in profit. The company's net worth Soared by an impressive increase of 18.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Flexxon Biosciences?
In 2022, Flexxon Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹14.00 M
₹0
Charges Breakdown by Lending Institutions
- Indian Bank : 1.40 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Feb 2023 | Indian Bank | ₹4.00 M | Open |
| 25 Aug 2021 | Indian Bank | ₹1.00 Cr | Open |
How Many Employees Work at Flexxon Biosciences?
Unlock and access historical data on people associated with Flexxon Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Flexxon Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Flexxon Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.